CompletedNCT00566020
Long-term lamotrigine safety in bipolarity type I
About this title
A Clinical Evaluation Of BW430C (Lamotrigine) In Bipolar I Disorder- Long-term Extension Of Study SCA104779 (NCT00550407) -
Read the official source — NCT00566020Medication studyAges 20+Japan
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 20 years. Other eligibility criteria applied.
- Listed locations
- Aichi and 51 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMay 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 92
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Japan
- Age range
- Over 20 Years
- Official registry ID
- NCT00566020
- Official title
Show the full official title
Study SCA106052, a Clinical Evaluation of BW430C (Lamotrigine) in Bipolar I Disorder- Long-term Extension Study (Extension of Study SCA104779 (NCT00550407))
Get this study by email
Recruitment & locations
CompletedAichi · Chiba · Fukuoka
17 more locations
- Gunma
- Hiroshima
- Hokkaido
- Ibaraki
- Kanagawa
- Kumamoto
- Kyoto
- Mie
- Nara
- Okayama
- Osaka
- Ōita
- Saga
- Saitama
- Tokyo
- Tottori
- Yamagata
Questions about this study
Who is behind this study?
The study sponsor is GlaxoSmithKline.
Did this study involve medication?
Yes. The study involved medication, including BW430C (lamotrigine).
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 20 years. Other eligibility criteria applied.
